Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
KETAMINE HCL vs ETOMIDATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Noncompetitive NMDA receptor antagonist; blocks glutamate binding, and modulates opioid receptors, monoaminergic receptors, and voltage-gated calcium channels.
Etomidate is a nonbarbiturate hypnotic agent that acts as a positive allosteric modulator of the gamma-aminobutyric acid (GABA) type A receptor, enhancing GABA-mediated inhibition in the central nervous system. It produces rapid anesthesia with minimal cardiovascular and respiratory depression.
Induction and maintenance of general anesthesia,Procedural sedation and analgesia,Treatment-resistant depression (off-label),Acute pain management (off-label)
Induction of general anesthesia,Procedural sedation (off-label),Rapid sequence intubation (off-label)
Induction: 1-2 mg/kg IV; Maintenance: 0.5-1 mg/kg IV or 10-30 mcg/kg/min IV infusion; Subanesthetic: 0.1-0.5 mg/kg IV; Analgesic: IM 2-4 mg/kg; Intranasal 1-3 mg/kg. Frequency: single doses or continuous infusion per clinical need.
Induction: 0.2–0.6 mg/kg IV over 30–60 seconds. Maintenance: 10–20 mcg/kg/min IV continuous infusion.
Terminal elimination half-life: 2–4 hours (alpha: 10–15 min, beta: 2.5–4 hr); prolonged in hepatic impairment and with repeated dosing (up to 12–24 hr for active metabolite norketamine).
Terminal elimination half-life: 2.9–5.3 hours (context: redistribution shortens clinical effect; hepatic impairment prolongs).
Hepatic; primarily via CYP3A4 and CYP2B6 to norketamine (active metabolite), then further metabolized by CYP2B6 and CYP2A6.
Etomidate is extensively metabolized in the liver via hydrolysis of the ester side chain by hepatic esterases to its principal metabolite, etomidate carboxylic acid. A minor metabolite is formed via N-demethylation. Metabolites are inactive.
Renal: 90% as metabolites (norketamine, dehydronorketamine, hydroxylated derivatives) and 4% unchanged; biliary/fecal: 3%; minor pulmonary exhalation.
Renal: 75% as metabolite (carboxylic acid), 2% unchanged; fecal/biliary: minimal.
47% bound primarily to albumin and alpha-1-acid glycoprotein.
76% bound to albumin.
2–4 L/kg (large distribution due to high lipophilicity; deep tissue compartments).
Vd: 2.5–4.5 L/kg (large, indicating extensive tissue uptake).
IM: 93%; intranasal: 45–50%; oral: 17–20% (extensive first-pass metabolism).
IV: 100% (only route used clinically).
No dose adjustment required for mild to moderate renal impairment (e GFR >=30 m L/min). Severe renal impairment (e GFR <30 m L/min): use with caution; no specific dosing guidelines; consider reduced doses and monitor for prolonged effects.
No dose adjustment required for renal impairment. Hemodialysis does not alter dosing. Use caution in severe renal failure due to propylene glycol vehicle if prolonged infusion.
Child-Pugh A: no adjustment. Child-Pugh B: consider 50% dose reduction. Child-Pugh C: avoid use or use extreme caution with significant dose reduction (e.g., 75% reduction) and monitor closely.
No specific adjustment for Child-Pugh class. However, prolonged effect may occur in severe hepatic impairment; reduce induction dose by 50% and titrate to effect.
Induction: 1-2 mg/kg IV; Maintenance: 0.5-1 mg/kg IV bolus or 5-20 mcg/kg/min IV infusion; IM: 2-5 mg/kg; Intranasal: 1-3 mg/kg. For procedural sedation: IV 0.5-1 mg/kg over 2-3 minutes; additional doses 0.25-0.5 mg/kg as needed. Weight-based dosing per kg.
Induction: 0.2–0.6 mg/kg IV (max 40 mg). Age >10 years: use adult dosing. Neonates and infants: reduce dose to 0.3 mg/kg due to higher volume of distribution.
Elderly patients: start with lowest effective doses; typical induction dose 0.5-1 mg/kg IV; reduce maintenance infusion rates (e.g., 5-10 mcg/kg/min); monitor for increased sensitivity, cognitive impairment, and cardiovascular effects; consider dose reduction of 25-50% compared to younger adults.
Induction: 0.15–0.3 mg/kg IV (50% reduction of adult dose) due to decreased clearance and increased sensitivity. Use lower end of dosing range.
None.
Etomidate has been associated with mortality in children. It should not be used in children younger than 6 months of age. (This warning is included in the prescribing information based on FDA labeling; specific text may vary.)
Emergence reactions (delirium, hallucinations) can occur; minimize with benzodiazepines.,Hemodynamic instability: increased heart rate and blood pressure (contraindicated in hypertension/aneurysm).,Potential for abuse and dependence; schedule III controlled substance.,Laryngospasm and respiratory depression, especially at higher doses.,Increased intracranial pressure and intraocular pressure.
Inhibition of adrenal steroidogenesis (adrenal suppression) due to blockade of 11-beta-hydroxylase, leading to decreased cortisol and aldosterone production; may persist for 12-24 hours after single dose,Myoclonic movements during induction (involuntary muscle contractions),Hypotension and bradycardia (less common than with other induction agents),Venous irritation and pain on injection (may be reduced by using larger veins)
Hypersensitivity to ketamine or any component,Conditions where significant blood pressure elevation is hazardous (e.g., aneurysms, uncontrolled hypertension),Severe coronary artery disease,Increased intracranial pressure or intraocular pressure,Pregnancy (only if benefit outweighs risk)
Hypersensitivity to etomidate,Patients with acute porphyria (may be porphyrinogenic)
No known food interactions. Avoid alcohol and grapefruit juice due to potential CYP3A4 inhibition affecting metabolism.
No specific food interactions are known. Etomidate is administered intravenously and does not have oral bioavailability. However, concurrent use of drugs that affect CYP3A4 (e.g., grapefruit juice) is not clinically significant due to IV route.
Fetal risk cannot be ruled out; animal studies show adverse effects at maternal toxic doses. Human data limited; avoid in first trimester unless benefits outweigh risks. Potential for fetal neurotoxicity in third trimester; use only if clearly needed.
Etomidate is classified as FDA Pregnancy Category C. Animal studies have shown embryotoxicity and teratogenicity at doses higher than human doses. There are no adequate and well-controlled studies in pregnant women. First trimester exposure may be associated with a slightly increased risk of congenital malformations, but data are limited. Risks to the fetus should be weighed against the benefits of maternal anesthesia. The drug is not recommended during pregnancy unless clearly needed, especially during organogenesis. In the second and third trimesters, etomidate may cause fetal central nervous system depression and respiratory depression if used near term.
M/P ratio unknown; ketamine enters breast milk in low amounts. Limited data; monitor infant for sedation. Weigh benefits against potential risks.
It is unknown whether etomidate is excreted in human breast milk. The molecular weight (244.3) suggests potential excretion into milk. The milk-to-plasma ratio (M/P) has not been determined. Due to the short half-life (2–5 hours) and use as a single induction dose, transfer to the infant is likely minimal. However, caution is advised. The American Academy of Pediatrics classifies etomidate as 'compatible' with breastfeeding after a single dose, but data are insufficient for repeated or prolonged use. Infants should be monitored for sedation and respiratory depression.
No specific dose adjustments required for pregnancy; consider increased volume of distribution and clearance. Use lowest effective dose; titrate to desired effect with careful monitoring.
No specific dose adjustments are recommended for etomidate during pregnancy, but the dose should be individualized to achieve the desired level of anesthesia with the lowest effective dose. Physiologic changes in pregnancy (e.g., increased plasma volume, altered protein binding) may affect pharmacokinetics, but etomidate is rapidly redistributed and has a short duration of action. The standard induction dose of 0.2–0.6 mg/kg IV is used. Close monitoring of maternal and fetal status is advised. In cesarean section, lower doses may be considered to reduce fetal depression.
Ketamine produces dissociative anesthesia with preserved airway reflexes and spontaneous respiration. Onset is rapid (30 seconds IV, 5 minutes IM). Emergence reactions (hallucinations, delirium) can be mitigated with benzodiazepines. Contraindicated in patients with elevated intracranial or intraocular pressure, hypertension, and severe coronary artery disease. Use with caution in psychiatric disorders. Subanesthetic doses are used for treatment-resistant depression and acute pain.
Etomidate is an induction agent of choice in hemodynamically unstable patients due to minimal cardiovascular depression. Adrenal suppression occurs even after a single dose, manifesting as decreased cortisol and aldosterone synthesis via 11β-hydroxylase inhibition. Administer slowly over 30-60 seconds to reduce myoclonus and pain on injection. Use a lower dose (0.2-0.3 mg/kg IV) in elderly or debilitated patients. Etomidate is not recommended for rapid sequence intubation in septic shock due to risk of adrenal insufficiency; consider ketamine as alternative. Prolonged infusion is not advised due to propylene glycol vehicle and adrenal suppression.
You may experience vivid dreams or confusion as the medication wears off.,Do not drive or operate machinery for at least 24 hours after receiving ketamine.,Avoid alcohol and other sedatives for 24 hours following treatment.,Inform your doctor if you have a history of high blood pressure, glaucoma, or psychiatric illness.,This medication may cause changes in perception or feeling of detachment during administration.
You may experience brief involuntary muscle movements during injection, which are usually harmless.,Tell your doctor if you have adrenal gland problems or are taking corticosteroids.,This drug may cause a temporary decrease in your body's ability to produce stress hormones.,Avoid driving or operating machinery until the effects of the medication have completely worn off.,Report any severe pain at the injection site or unusual weakness after the procedure.
"Butabarbital, a barbiturate, induces cytochrome P450 (CYP) enzymes, enhancing the hepatic metabolism of ketamine, a dissociative anesthetic primarily metabolized by CYP3A4 and CYP2B6. This interaction reduces ketamine's systemic exposure and anesthetic efficacy, potentially leading to suboptimal sedation or anesthesia. Additionally, concurrent use may increase the risk of respiratory depression and hypotension due to additive central nervous system (CNS) depressant effects."
"The combination of ketamine and diamorphine can lead to additive central nervous system (CNS) depression and respiratory depression, increasing the risk of hypoxia, sedation, and respiratory arrest. Ketamine, an NMDA receptor antagonist, enhances opioid-induced analgesia but also potentiates the adverse effects of diamorphine, including hypotension and bradycardia. Patients may experience profound sedation, confusion, and cardiovascular instability, particularly at higher doses or in opioid-naive individuals."
"Ketamine, an NMDA receptor antagonist, may inhibit cytochrome P450 3A4 (CYP3A4) activity, which is responsible for the 25-hydroxylation of cholecalciferol (vitamin D3) to calcidiol (25-hydroxyvitamin D). This inhibition can reduce the conversion of cholecalciferol to its active form, potentially leading to decreased vitamin D levels and impaired calcium homeostasis. Clinically, this may increase the risk of vitamin D deficiency, contributing to bone demineralization, hypocalcemia, or secondary hyperparathyroidism in patients receiving long-term or high-dose ketamine therapy."
"Concurrent administration of etomidate and fluoxetine may potentiate the anesthetic and sedative effects, as fluoxetine inhibits CYP3A4 which is involved in the metabolism of etomidate, leading to increased etomidate plasma concentrations and prolonged recovery time. Additionally, both drugs can cause QTc interval prolongation, increasing the risk of torsades de pointes and other ventricular arrhythmias. Patients may experience enhanced central nervous system depression, respiratory depression, and hypotension."
"The combination of Promazine, a phenothiazine antipsychotic with strong alpha-adrenergic blocking activity, and Etomidate, a non-barbiturate hypnotic used for induction of anesthesia, can lead to an increased risk of hypotension due to additive vasodilatory effects. Promazine's alpha-1 receptor antagonism impairs compensatory vasoconstriction, while Etomidate suppresses adrenal cortisol synthesis, potentially blunting the stress response and further reducing hemodynamic stability. Clinically, this interaction may result in profound hypotension, especially in hypovolemic or elderly patients, requiring careful dose titration and monitoring."
"The coadministration of oxazepam, a benzodiazepine that enhances GABA-A receptor activity, with etomidate, a non-barbiturate anesthetic that also potentiates GABA-A receptor function, results in additive central nervous system (CNS) depression. This synergistic interaction can lead to excessive sedation, respiratory depression, hypotension, and prolonged recovery from anesthesia. Patients are at increased risk of apnea, hypoxia, and hemodynamic instability, particularly during induction and maintenance of anesthesia."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about KETAMINE HCL vs ETOMIDATE, answered by our medical review team.
KETAMINE HCL is a General Anesthetic that works by Noncompetitive NMDA receptor antagonist; blocks glutamate binding, and modulates opioid receptors, monoaminergic receptors, and voltage-gated calcium channels.. ETOMIDATE is a General Anesthetic that works by Etomidate is a nonbarbiturate hypnotic agent that acts as a positive allosteric modulator of the gamma-aminobutyric acid (GABA) type A receptor, enhancing GABA-mediated inhibition in the central nervous system. It produces rapid anesthesia with minimal cardiovascular and respiratory depression.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between KETAMINE HCL and ETOMIDATE depend on the specific clinical indication. These are both General Anesthetic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of KETAMINE HCL is: Induction: 1-2 mg/kg IV; Maintenance: 0.5-1 mg/kg IV or 10-30 mcg/kg/min IV infusion; Subanesthetic: 0.1-0.5 mg/kg IV; Analgesic: IM 2-4 mg/kg; Intranasal 1-3 mg/kg. Frequency: single doses or continuous infusion per clinical need.. The standard adult dose of ETOMIDATE is: Induction: 0.2–0.6 mg/kg IV over 30–60 seconds. Maintenance: 10–20 mcg/kg/min IV continuous infusion.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between KETAMINE HCL and ETOMIDATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. KETAMINE HCL is classified as Category C. Fetal risk cannot be ruled out; animal studies show adverse effects at maternal toxic doses. Human data limited; avoid in first trimester unless benefits outweigh risks. Potential . ETOMIDATE is classified as Category C. Etomidate is classified as FDA Pregnancy Category C. Animal studies have shown embryotoxicity and teratogenicity at doses higher than human doses. There are no adequate and well-co. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.